Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POLARIS-4: Vosevi vs Epclusa in DAA-Experienced HCV
NCT02639247Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Dec 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 8
01
Overview
A Phase 3 trial of voxilaprevir in hepatitis C (HCV), sponsored by Gilead Sciences. Started Dec 2015; status: completed.
02
Drugs
voxilaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02639247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02639247.